Cure My Disease

Don't miss your cure!

 Log in / Sign up

Experimental CAR-T therapy takes on Hard-to-Treat lupus nephritis

NCT ID NCT06342960

Ongoing Disease control Sponsor: Kyverna Therapeutics Source: ClinicalTrials.gov ↗

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 2 times

Summary

This early-phase trial is testing a personalized cell therapy called KYV-101 for people with lupus nephritis that hasn't responded to standard treatments. The therapy uses a patient's own immune cells, modified to target and destroy faulty B cells that drive the disease. Only 2 participants are enrolled, and the main goal is to check safety and how the therapy affects the immune system.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance
KYV-101 CAR-T cell therapy (a personalized immune cell treatment) plus standard chemotherapy drugs (cyclophosphamide and fludarabine) to prepare the body
What this could lead to
If successful, this could point toward a new way to control severe lupus nephritis by resetting the immune system, potentially reducing the need for lifelong medications.
What could go wrong
This is a very early, tiny trial with only 2 participants, so results may not apply to others. CAR-T therapy carries risks like severe immune reactions and infections, and it is not yet known if it can safely control lupus long-term.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for LUPUS NEPHRITIS are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

autoimmune disease glomerulonephritis lupus nephritis systemic lupus erythematosus

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

LUPUS NEPHRITIS LUPUS NEPHRITIS - WHO CLASS III LUPUS NEPHRITIS - WHO CLASS IV

Contacts and locations

Locations

  • Charite- Universitätsklinikum Berlin

    Berlin, Germany

  • Fraunhofer-Institut für Translationale Medizin und Pharmakologie ITMP

    Frankfurt, Germany

  • Universitätsklinikum Carl Gustav Carus Dresden

    Dresden, Germany

  • Universitätsklinikum Düsseldorf

    Düsseldorf, Germany

  • Universitätsklinikum Erlangen

    Erlangen, Germany

  • Universitätsklinikum Hamburg-Eppendorf

    Hamburg, Germany

More trials for these conditions

Other studies related to the condition(s) this trial covers.